RU2019135842A3 - - Google Patents

Download PDF

Info

Publication number
RU2019135842A3
RU2019135842A3 RU2019135842A RU2019135842A RU2019135842A3 RU 2019135842 A3 RU2019135842 A3 RU 2019135842A3 RU 2019135842 A RU2019135842 A RU 2019135842A RU 2019135842 A RU2019135842 A RU 2019135842A RU 2019135842 A3 RU2019135842 A3 RU 2019135842A3
Authority
RU
Russia
Application number
RU2019135842A
Other languages
Russian (ru)
Other versions
RU2813816C2 (ru
RU2019135842A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019135842A publication Critical patent/RU2019135842A/ru
Publication of RU2019135842A3 publication Critical patent/RU2019135842A3/ru
Application granted granted Critical
Publication of RU2813816C2 publication Critical patent/RU2813816C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2019135842A 2017-04-11 2018-04-11 Полиспецифические полипептидные конструкции, обладающие ограниченным связыванием с сd3, и способы их применения RU2813816C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484217P 2017-04-11 2017-04-11
US62/484,217 2017-04-11
PCT/US2018/027195 WO2018191438A1 (en) 2017-04-11 2018-04-11 Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2023127070A Division RU2023127070A (ru) 2017-04-11 2018-04-11 Полиспецифические полипептидные конструкции, обладающие ограниченным связыванием с cd3, и способы их применения

Publications (3)

Publication Number Publication Date
RU2019135842A RU2019135842A (ru) 2021-05-12
RU2019135842A3 true RU2019135842A3 (cg-RX-API-DMAC7.html) 2022-01-25
RU2813816C2 RU2813816C2 (ru) 2024-02-19

Family

ID=

Also Published As

Publication number Publication date
IL269826B2 (en) 2026-01-01
BR112019020940A2 (pt) 2020-05-05
US11866507B2 (en) 2024-01-09
IL269826A (en) 2019-11-28
JP7798942B2 (ja) 2026-01-14
MY200973A (en) 2024-01-26
KR20200005732A (ko) 2020-01-16
JP7450684B2 (ja) 2024-03-15
CN110770255B (zh) 2025-07-01
EP3619235A1 (en) 2020-03-11
TW202515920A (zh) 2025-04-16
US20190010242A1 (en) 2019-01-10
MX2019012198A (es) 2020-01-21
CN120607624A (zh) 2025-09-09
AU2018250641A1 (en) 2019-10-31
SA519410284B1 (ar) 2025-04-26
JP2023002686A (ja) 2023-01-10
AU2018250641B2 (en) 2025-03-13
JP2020516287A (ja) 2020-06-11
IL269826B1 (en) 2025-09-01
US20240101704A1 (en) 2024-03-28
MX2024005371A (es) 2024-05-20
SG11201909160WA (en) 2019-10-30
TW201843177A (zh) 2018-12-16
CN110770255A (zh) 2020-02-07
JP2024063176A (ja) 2024-05-10
NZ758264A (en) 2023-08-25
JP7164544B2 (ja) 2022-11-01
KR102732040B1 (ko) 2024-11-21
WO2018191438A1 (en) 2018-10-18
AU2025204373A1 (en) 2025-07-03
JP2026040675A (ja) 2026-03-09
TWI871272B (zh) 2025-02-01
PH12019502303A1 (en) 2020-09-28
CA3058477A1 (en) 2018-10-18
KR20240165484A (ko) 2024-11-22
RU2019135842A (ru) 2021-05-12

Similar Documents

Publication Publication Date Title
BR122021000189A2 (cg-RX-API-DMAC7.html)
BR112019008823A2 (cg-RX-API-DMAC7.html)
BR112020006084A8 (cg-RX-API-DMAC7.html)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020006283B1 (pt) Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico
BR112020009729B1 (pt) Inibidores de acss2 e métodos de uso dos mesmos
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112020001262B1 (pt) Processo para preparar uma composição de entrega de fármaco
BR112020000320B1 (pt) Dispositivo bioerodível de administração de fármacos, seu método de preparação, e uso de uma folha não-tecido
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112020001354B1 (pt) Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR102018003507B1 (pt) Sistema de isolamento de tensão de tambor de guincho
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019014127B1 (pt) Composição farmacêutica para tratamento de tumores
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR102017026429B1 (pt) Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros